ReviewBreathe (Sheffield, England)2016
Global impact of bronchiectasis and cystic fibrosis.
Review in Breathe (Sheffield, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719597 (Effects of Positive Expiratory Pressure Breathing Versus Incentive Spirometry on Dyspnea and Sputum Profile in Bronchiolectasis Patients), which is not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Positive Expiratory Pressure Breathing Versus Incentive Spirometry on Dyspnea and Sputum Profile in Bronchiolectasis Patients
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Intermittent prophylactic antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2022Pooled it
- Continuous versus intermittent antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018Pooled it
- Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in respiratory diseasePooled it
- Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.Lancet (London, England) · 2018Trial
- Prevalence of Cystic Fibrosis and Pattern of Lung Function Impairment in Adults Presenting With Bronchiectasis at a Tertiary Care Hospital in Resource Poor Country Bangladesh: A Cross-Sectional Study.Health science reports · 2026Article
- Ataxia-Telangiectasia and Associated Bronchiectasis: Case Report and Literature Review.Journal of clinical medicine · 2026Review
- Patient-reported outcome measures developed for non-cystic fibrosis bronchiectasis may be applied to cystic fibrosis bronchiectasis.Health and quality of life outcomes · 2026Article
- Microbiological Analysis Following Periodontal Treatment in Individuals with Bronchiectasis.Microorganisms · 2026Article
- Psychological impact of genetic eligibility for CFTR modulator therapy in children with cystic fibrosis and their parents.European journal of pediatrics · 2026Article
- Determinants of Bronchiectasis Among Patients Attending Chest Clinic of Teaching Hospital in Ethiopia: Case-Control Study.Pulmonary medicine · 2026Article
- The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy.Annals of the American Thoracic Society · 2026Review
- Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target.The European respiratory journal · 2025Review
- Decoding the causal association between immune cells and three chronic respiratory diseases: Insights from a bi-directional Mendelian randomization study.BMC pulmonary medicine · 2025Article
- Athletic protocol in non-cystic fibrosis-related bronchiectasis: rationale and design of the pilot ATHOS study.Frontiers in medicine · 2025Article
- Targeting neutrophil serine proteases in bronchiectasis.The European respiratory journal · 2025Review
- Decoding the diagnostic and therapeutic potential of microbiota using pan-body pan-disease microbiomics.Nature communications · 2024Article
- Article
- Recreating chronic respiratory infectionsEuropean respiratory review : an official journal of the European Respiratory Society · 2024Review
- Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Bronchiectasis-associated infections and outcomes in a large, geographically diverse electronic health record cohort in the United States.BMC pulmonary medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EDUCATIONAL
aimsTo recognise the clinical and radiological presentation of the spectrum of diseases associated with bronchiectasis.To understand variation in the aetiology, microbiology and burden of bronchiectasis and cystic fibrosis across different global healthcare systems. Bronchiectasis is the term used to refer to dilatation of the bronchi that is usually permanent and is associated with a clinical syndrome of cough, sputum production and recurrent respiratory infections. It can be caused by a range of inherited and acquired disorders, or may be idiopathic in nature. The most well recognised inherited disorder in Western countries is cystic fibrosis (CF), an autosomal recessive condition that leads to progressive bronchiectasis, bacterial infection and premature mortality. Both bronchiectasis due to CF and bronchiectasis due to other conditions are placing an increasing burden on healthcare systems internationally. Treatments for CF are becoming more effective leading to more adult patients with complex healthcare needs. Bronchiectasis not due to CF is becoming increasingly recognised, particularly in the elderly population. Recognition is important and can lead to identification of the underlying cause, appropriate treatment and improved quality of life. The disease is highly diverse in its presentation, requiring all respiratory physicians to have knowledge of the different "bronchiectasis syndromes". The most common aetiologies and presenting syndromes vary depending on geography, with nontuberculous mycobacterial disease predominating in some parts of North America, post-infectious and idiopathic disease predominating in Western Europe, and post-tuberculosis bronchiectasis dominating in South Asia and Eastern Europe. Ongoing global collaborative studies will greatly advance our understanding of the international impact of bronchiectasis and CF.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.